BIOMAT Database Logo BIOMAT Database Logo

Phase II trial of fludarabine in patients with epithelial ovarian cancer. 1986

J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D001084 Vidarabine Phosphate An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties. Adenine Arabinoside Monophosphate,Ara-AMP,Arabinofuranosyladenine Monophosphate,Vidarabine Monophosphate,9-(5-O-Phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine,Ara AMP,Monophosphate, Adenine Arabinoside,Monophosphate, Arabinofuranosyladenine,Monophosphate, Vidarabine,Phosphate, Vidarabine
D001088 Arabinonucleotides Nucleotides containing arabinose as their sugar moiety. Arabinofuranosylnucleotides

Related Publications

J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
December 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
January 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
Phase II evaluation of bleomycin in patients with advanced epithelial ovarian cancer.
March 1984, Cancer treatment reports,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer.
January 1988, Cancer chemotherapy and pharmacology,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer.
September 2005, British journal of cancer,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer.
May 1986, Gynecologic oncology,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.
February 1999, Gynecologic oncology,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer.
January 1986, Gynecologic oncology,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer.
April 1992, British journal of cancer,
J J Kavanagh, and C A Stringer, and L J Copeland, and D M Gershenson, and P Saul
Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
June 2019, Gynecologic oncology,
Copied contents to your clipboard!